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Radiation therapy is a powerful tool for the treatment of oesophageal cancer. We established radioresistant cell lines by applying
fractionated irradiation in order to identify differentially expressed genes between parent and radioresistant cells. Six oesophageal
cancer cell lines (TE-2, TE-5, TE-9, TE-13, KYSE170, and KYSE180) were treated with continuous 2Gy fractionated irradiation (total
dose 60Gy). We compared expression profiles of each parent and radioresistant lines on a cDNA microarray consisting of 21168
genes. In the fractionated irradiation trial, four radioresistant sublines (TE-2R, TE-9R, TE-13R, KYSE170R) were established
successfully, and we identified 19 upregulated and 28 downregulated genes common to radioresistant sublines. Upregulated genes
were associated with apotosis and inflammatory response (BIRC2 and COX-2), DNA metabolism (CD73), and cell growth (PLAU).
Downregulated genes were associated with apoptosis (CASP6), cell adhesion (CDH1 and CDH3), transcription (MLL3), and cell
cycle (CDK6). Some of these genes were known to be associated with radiation response, such as COX-2, but others were novel.
Reverse transcription–polymerase chain reaction confirmed that genes selected by cDNA microarray were overexpressed in clinical
specimens of radioresistant cases. Global gene analysis of radioresistant sublines may provide new insight into mechanisms of
radioresistance and effective radiation therapy.
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Radiation therapy for oesophageal cancer is effective in selected
patients but there are patients who show no response and suffer
from side effects such as immunosuppression. Many factors
determine tumour resistance in clinical radiotherapy, including
tumour size, hypoxia, and intrinsic radiosensitivity. Clinical data
suggest that size is one of the most important factors to predict
outcome for cancer patients after radiotherapy (Eifel et al, 1994).
The most obvious explanation for this is related to the number of
clonogenic cells that must be sterilised. However, because of
heterogeneity in both patient and tumour characteristics, the
volume effect is less pronounced than would be expected from a
simple proportionality between the number of clonogenes and
volume.
Chronic exposure of cells to an ionising radiation induces an
adaptive response that results in increased tolerance to the
subsequent cytotoxicity caused by this ionising radiation (Russell
et al, 1995; Dahlberg et al, 1999; Pearce et al, 2001). Although the
factor that ultimately determines a cell’s radiosensitivity is quite
complex, several researchers have pointed out that the induction of
apoptosis is correlated with the biological effectiveness of the
radiation (Dewey et al, 1995; Meyn et al, 1996). To investigate
clinical radioresistance, regimens of fractionated ionising radiation
(FIR) in vitro have been used to determine molecular mechanisms
underlying radioresistance. Tumour cells are heterogeneous with
respect to cure-limiting characteristics, and the radioresistant
phenotype is correlated often with several factors, including
alterations in cell cycle checkpoints, slowed growth, and decreased
apoptosis (Coleman and Stevenson, 1996; Maity et al, 1997).
Recently, a relationship between radioresistance and expression of
several genes has been reported, including p53 (Brachman et al,
1993; Biard et al, 1994), ras (Sklar, 1988), raf-1 (Kasid et al, 1987),
and bcl-2 (Kitada et al, 1996). Biard et al (1994) reported the first
model in which cells bearing a p53 gene mutation display
enhanced sensitivity to ionising radiation, although Brachman
et al (1993) reported that the p53 gene mutation does not correlate
with the radiosensitivity of 24 head and neck cancer cell lines. The
activation of raf has been positively correlated with the radio-
resistance of head and neck squamous cell carcinomas (Riva et al,
1995), and certain cell cycle- and apoptosis-related genes have also
been correlated with radiosensitivity; for example, loss or
dysfunction of p16 renders resistance to melanoma cells against
the ionising radiation, whereas the expression of exogenous wild-
type p16 and p21 in glioblastoma cells can induce radiosensitivity
(Hsiao et al, 1997; Matsumura et al, 1997). Overexpression of bcl-2
in multiple tumour cells increases radiation resistance (Gasparini
et al, 1995; Weller et al, 1995; Mackey et al, 1998), and bax, the
other number of the bcl-2 family, antagonises the bcl-2 function by
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develop a partial understanding of the molecular mechanisms
responsible for cellular radiosensitivity, the entire process still
remains to be elucidated. The advent of microarray gene
expression technology permits the simultaneous analysis of the
expression levels of thousands of genes (DeRisi et al, 1996; Eisen
et al, 1998; Golub et al, 1999). Therefore, a study on these
molecular genetic events, which are related to radiosensitivity,
can be conducted (Hanna et al, 2001; Kitahara et al, 2002). This
may also lead to identifying and gene regulatory pathways
resulting in the development of cell resistance to therapeutic
procedure. However, little is known about the clinical significance
of these genes in order to estimate radiotherapy effectiveness.
We have tried to identify differentially expressed genes between
radiosensitive and radioresistant oesophageal cancer cell lines.
Radioresistant sublines were established by FIR, and we applied
cDNA microarrays to the parent and radioresistant sublines.
Finally, for the clinical application of selected genes, we studied the
expression status of COX-2 and BIRC2 mRNA in biopsy specimens
obtained from ‘radio-effective’ and ‘noneffective’ cases of oeso-
phageal cancer.
MATERIALS AND METHODS
Cells and cell culture
The human oesophageal squamous cancer cell lines TE-2, TE-5,
TE-9, and TE-13 were obtained from the Cell Resource Center for
Biomedical Research Institute of Development, Aging and Cancer
(Tohoku University, Sendai, Japan) (Nishihira et al, 1993). Cell
lines KYSE170 and KYSE180 were kindly provided by Dr Shimada
(Kyoto University, Kyoto, Japan) (Shimada et al, 1992). Cells were
cultured in RPMI-1640 (Life Technologies, Grand Island, NY, USA)
with 100Uml
 1 of penicillin. 100mgml
 1 of streptomycin, and
10% fetal bovine serum, and incubated at 371Ci n5 %C O 2/95% air.
Establishment of radioresistant cell lines
The cells were first grown to approximately 50% confluence in
vented 25-cm
2 culture flasks. Cells were treated with 2Gy of X-ray
irradiation (120kV and 3.5mA for 4min with a 0.5-mm A1 filter)
using an X-ray generator (M-150 WE: SOFTEX Co., Tokyo, Japan)
and then returned to the incubator. When they reached
approximately 90% confluence, the cells were trypsinised and
subcultured into new flasks. When they reached approximately
50% confluence, the cells were again irradiated (second fraction).
The fractionated irradiations were continued until the total doses
reached 60Gy. The parental cells were subjected to identical
trypsinisation, replating, and culture conditions but were not
irradiated. For all assays on irradiated cells, there was at least a
2-week interval between the last 2Gy FIR and the experiment.
Assay for radiosensitivity
Cell survival after X-irradiation was measured by clonogenic assay.
The cells (10
5 cells per dish) were incubated at 371C for 48h in the
growth medium and were irradiated at different doses ranging
from 0 to 10Gy. The cells were harvested with EDTA–trypsin
immediately after irradiation. Subsequently, a constant number of
cells were plated in each 60-mm tissue culture dish (Iwaki Glass,
Chiba, Japan), and incubated at 371C for 10–14 days (three plates
in each radiation dose). After fixation with formalin and staining
with 0.1% crystal violet, colonies consisting of 50 cells or more
were counted under a light microscope, and the surviving fraction
was determined.
All survival curves represent at least three independent
experiments. The data were fitted to the single hit, multitarget
formula, where survival (S) is related to dose (D) by the expression
S ¼ 1  ð 1   e DD0Þ
nAne DD0. D0 was used as a parameter to
indicate the amount of irradiation required to reduce the survival
fraction to approximately 0.37 from the survival curve.
Flow cytometry
Cells were analysed during exponential growth. They were
trypsinised, rinsed in PBS, and fixed in 70% ethanol. Before
analysis, cells were spun out of ethanol and resuspended in 1.6ml
PBS, 0.2ml propidium iodide (PI) 400mgml
 1 (Sigma Chemical
Co., Poole, UK), and 0.2ml RNase 1mgml
 1 (Sigma). After
incubation for 30min at 371C, the cells were spun down and
resuspended in PBS. The cells were analysed by a FACScan flow
cytometer (Becton Dickinson, San Jose, CA, USA) for DNA content
using PI and a photomultiplier masked with a 610nm long-pass
filter. The data were analysed with a software program (Cell Quest;
Becton Dickinson) with dead cells gated out using pulse processing.
Two independent experiments were performed for each data set.
RNA extraction
Total RNA was extracted from each cell line with the RNeasy Midi
Kit (QIAGEN) according to the manufacturer’s protocol. The
extracted RNA was treated with RNase-Free DNase set (QIAGEN)
to remove any contamination of genomic DNA according to the
manufacture’s protocol.
Microarray design, production, and hybridisation
A2 0 mg portion of total RNA extracted from each radioresistant
subline was labelled with Cy3, and RNA from each parent cell line
was labelled with Cy5 as described elsewhere (Sakakura et al,
2002). We used the RIKEN human cDNA microarray, which
contains 21168 genes. Hybridisation, washing, and scanning were
carried out according to a published method (Sakakura et al,
2002). These slides were scanned on a ScanArray 5000 confocal
laser scanner, and the images were analysed using IMAGENE (Bio
Discovery, Los Angeles, CA, USA).
Analysis of the data
To improve the accuracy of the data, we did the experiment twice,
labelling the same RNA template in two separate reactions. Data
were normalised to the reference standard by subtracting (in log
space) the median observed value if other than zero. We used only
data points that were reproducible. To this end, we developed a
filtering program, PRIM (Kaota et al, 2001). After filtering was
finished, we compared the results of the two experiments by
calculating a Pearson’s correlation coefficient. If the coefficient was
equal to or greater than 0.7, we used the data in subsequent
analysis. Ratio values from duplicate experiments were averaged,
log-transformed (base 2), and stored in a table. Two-fold
differences in up- or downregulated expression were used to
identify altered genes. Hierarchical clustering and dendrogram
figures were generated using Cluster and Tree-View software
(http://rana.standford.edu).
Quantitative RT–PCR
A quantitative RT–PCR assay was used to follow-up on microarray
data. A 4mg portion of total RNA was used for creation of single-
stranded cDNA using the SuperScript Preamplification System for
First Strand cDNA Synthesis (Life Technologies Inc., Rockville,
MD, USA). The cDNA was diluted and quantitatively equalised for
PCR amplification. The TaqMan PCR method using a Gene Amp
5700 Sequence Detection System (Applied Biosystems, Foster City,
CA, USA) was performed according to the manufacturer’s
instructions. We used the primers and probes provided as
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tems). We used beta-actin as an internal control gene to normalise
the expression rate of each gene. The details have been described
elsewhere (Sakakura et al, 2004). Each experiment was carried out
three times and the average was calculated.
Clinical specimens
Eight patients with advanced squamous cell carcinoma of the
oesophagus (T3 or T4) treated with preoperative radiation
therapy at Kyoto Prefectural University of Medicine were
subjected to preliminary clinical analysis. Tissue samples were
obtained from the tumour site for an initial diagnostic biopsy,
and 10–40mg of total RNA was extracted, and cDNA was
synthesised from 4mg of total RNA as described. Preoperative
irradiation was performed with a dose of 2Gy per fraction to a
total dose of 40Gy. The effects of radiation therapy in the
resected specimens were determined using the histopathologic
criteria of the Japanese Society for Esophageal Disease. Grade 0
represents no radiotherapy effect; grade 1, slightly effective, with
viable cells recognised as more than one-third cancer cells; grade
2, moderately effective, with less than one-third cancer cells; and
grade 3, markedly effective, with no viable cancer cells. We
compared the expression rates of the selected genes for group A
(patients whose histological grade after radiotherapy was either 0
or 1) with those for group B (patients whose histological grade
after radiotherapy was either 2 or 3). A statistical analysis was
performed using the Mann–Whitney U-test. The results with P-
values of less than 0.05 were considered to be statistically
Table 1 Clonogenic survival parameters fitting the data to a multitarget
model
Cell line D0
[95% confidence
intervals] n
[95% confidence
intervals]
TE-2
Control 0.75 [0.68–0.84] 2.63 [1.49–4.63]
Resistant 1.05 [0.95–1.19] 2.85 [1.57–5.15]
TE-5
Control 0.69 [0.57–0.85] 13.97 [4.05–48.24]
Resistant 0.73 [0.65–0.85] 9.25 [4.21–20.29]
TE-9
Control 1.14 [1.00–1.32] 1.76 [1.21–2.55]
Resistant 1.71 [1.53–1.93] 1.60 [1.15–2.23]
TE-13
Control 1.49 [1.39–1.61] 2.42 [1.76–3.34]
Resistant 1.83 [1.70–1.98] 2.61 [1.97–3.45]
KYSE170
Control 1.31 [1.17–1.49] 2.46 [1.55–3.90]
Resistant 1.76 [1.49–2.17] 2.73 [1.38–5.37]
KYSE180
Control 0.91 [0.84–0.99] 2.43 [1.74–3.38]
Resistant 0.97 [0.89–1.07] 2.02 [1.43–2.84]
D0 was used as a parameter to indicate the amount of irradiation required to reduce
the survival fraction to approximately 0.37 from the survival curve.
Table 2 Cell cycle distributions of the cell lines
Cell line G1 S G2/M
TE-2
Control 54.9 18.1 27
Resistant 49 22.5 28.5
TE-9
Control 57.3 16.1 26.6
Resistant 60.8 17.2 21.9
TE-13
Control 49.5 23.9 26.6
Resistant 53.1 24.7 22.2
KYSE-170
Control 51.8 17 31.2
Resistant 56 16.7 27.3
Table 3 Upregulated genes in radioresistant sublines in comparison to parent cell lines
Function Accession Description TE-2 TE-9 TE-13 KYSE170
Apoptosis, inflammatory response AA418021 ICEBERG caspase-1 inhibitor (ICEBERG) 2.18 1.04 4.18 2.06
Apoptosis R44417 baculoviral IAP repeat-containing 2 (BIRC2) 2.23 2.28 1.57 2.96
Blood coagulation, cell growth AA284669 plasminogen activator, urokinase (PLAU) 2.64 2.48 1.11 3.23
Carbohydrate metabolism AA775378 mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-
acetylglucosaminyltransferase (MGAT1)
2.06 8.18 0.45 3.06
Cell adhesion, immune response AA458965 natural killer cell transcript 4 (NK4) 7.03 8.53 1.03 2.28
DNA metabolism R60343 50 nucleotidase (CD73) (NT5) 2.21 0.54 4.45 4.26
Electron transport AA418907 cytochrome P450, subfamily I (aromatic compound-
inducible), polypeptide 1 (CYP1A1)
7.19 2.19 0.41 2.67
Electron transport R33030 glucose regulated protein, 58kDa (GRP58) 2.80 2.11 1.51 3.22
Electron transport AA430497 protein disulphide isomerase related protein (calcium-
binding protein, intestinal-related) (ERP70)
9.78 2.92 1.11 2.94
Inflammatory response R80217 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H
synthase and cyclooxygenase) (PTGS2) (COX-2)
2.16 3.17 4.16 1.29
Protein amino-acid phosphorylation AA447574 protein kinase C, zeta (PRKCZ) 2.00 10.04 0.92 3.70
Protein amino-acid phosphorylation N94921 receptor tyrosine kinase-like orphan receptor 2 (ROR2) 2.05 0.95 5.06 2.30
Protein amino-acid phosphorylation H74007 serum/glucocorticoid regulated kinase (SGK) 4.04 2.20 2.51 1.00
Regulation of transcription, DNA-
dependent
AA293192 putative nucleic acid binding protein RY-1 (RY1) 2.17 2.32 1.00 2.37
Transport AA400973 lipocalin 2 (oncogene 24p3) (LCN2) 3.01 2.33 1.31 5.47
tRNA processing AA156571 alanyl-tRNA synthetase (AARS) 3.81 2.29 0.66 2.39
Unclassified T67069 GTP binding protein 2 (GTPBP2) 2.77 2.42 1.10 2.96
Unclassified N90081 tripartite motif protein TRIM8 (TRIM8) 2.28 2.35 0.99 6.68
Unclassified AA453410 tumour necrosis factor receptor superfamily, member 10b
(TNFRSF10B)
2.08 19.12 0.92 3.03
Representative functions of the genes as previously reported, accession number, gene name, and fold change of each radioresistant subline compared to their parent cell line are
shown. Only the genes that showed more than two-fold change in at least three of the four radioresistant sublines are sorted by cDNA microarray data.
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ysignificant. All experiments with clinical samples were conducted
under institutional guidelines from the Ministry of Health and
Welfare.
RESULTS
Establishment of cell lines resistant to irradiation
The human oesophageal cancer cell lines were treated with FIR, and all
cell lines survived. The cell populations surviving FIR were analysed
for their radiosensitivity using a clonogenic assay to assess survival
after a single dose of radiation. The survival curve parameters for all
cell lines are shown in Table 1. There was a significant increase in
radioresistance in the TE-2R, TE-9R, TE-13R, and KYSE-170R sublines
compared to parental cell lines. Therefore, we considered these four
sublines (TE-2R, TE-9R, TE-13R, and KYSE-170R) as radioresistant.
All radioresistant sublines maintained a radioresistant phenotype for
at lease 3 months after the cessation of FIR (data not shown).
Cell cycle analysis
Cells in S phase tend to be more radiosensitive than cells in G1,
and cells in G2–M are the most sensitive of all (Sinclair and
Morton, 1966). Therefore, we examined the cell cycle distribution
of cell lines using flow cytometry. The results in Table 2 show that,
when in exponential growth, the lines have very similar cell cycle
distributions and thus cannot be the explanation for the altered
radiosensitivity of resistant cells. Other experiments also showed
similar results (data not shown).
Gene selection from cDNA microarray data analysis
We performed global expression analysis of 21168 genes using a
high-density cDNA microarray and compared the four profiles of
parent lines and radioresistant sublines. We identified 47 genes as
differentially expressed in at least three of the four radioresistant
sublines. In all, 19 genes were upregulated (Table 3), and 28 were
downregulated (Table 4). Upregulated genes were associated with
apoptosis and inflammatory response (ICEBERG, BIRC2, and
COX-2), DNA metabolism (CD73), and cell growth (PLAU). Other
areas of upregulation included electron transport (CYP1A1,
GRP58, and ERP70) and protein amino-acid phosphorylation
(PRKCZ, ROR2, and SGK). Downregulated genes were associated
with apoptosis (CASP6), cell adhesion (CDH1, CDH3, and
PCDH9), and transcription (MLL3 and PRKCBP1), as well as cell
cycle (CDK6 and CCNA2).
To verify the expression of genes identified in microarray
experiments, real-time quantitative RT–PCR was performed using
the same RNA as that used in the microarray analysis. We found
that the results were in good agreement with those from the
microarray data. Typical data for COX-2 and BIRC2 are shown in
Figure 1.
Effects of radiotherapy and expression of selected genes
in clinical specimens
In eight cases of squamous cell carcinoma of the oesophagus,
COX-2 and BIRC2 mRNA expressions of pretreatment biopsy
samples were assayed by quantitative RT–PCR. Although the
Table 4 Downregulated genes in radioresistant sublines in comparison to parent cell lines
Function Accession Description TE-2 TE-9 TE-13 KYSE170
Apoptosis W45688 caspase 6, apoptosis-related cysteine protease (CASP6) 0.09 0.14 0.04 0.04
Carbohydrate metabolism AA193116 glycerol-3-phosphate dehydrogenase 1 (soluble) (GPD1) 1.64 0.37 0.44 0.37
Cell adhesion H97778 cadherin 1, type 1, E-cadherin (epithelial) (CDH1) 0.05 0.25 0.07 0.02
Cell adhesion AA425217 cadherin 3, type 1, P-cadherin (placental) (CDH3) 0.05 0.22 0.03 0.02
Cell adhesion N63057 protocadherin 9 (PCDH9) 0.43 0.07 0.69 0.36
Cell growth, cell–cell signalling W56771 endometrial bleeding associated factor (left–right
determination, factor A; transforming growth factor beta
superfamily) (EBAF)
0.45 1.00 0.19 0.40
Epidermal differentiation W23757 keratin 13 (KRT13) 0.37 0.30 3.32 0.19
Intracellular protein transport R28020 RAB2, member RAS oncogene family (RAB2) 0.07 0.20 0.03 0.03
Intracellular signalling cascade R91570 signal transducer and activator of transcription 4 (STAT4) 0.19 0.12 0.09 0.06
Ion transport T52201 chloride intracellular channel 2 (CLIC2) 0.60 0.40 0.48 0.32
Metabolism AA668821 chitinase 3-like 2 (CHI3L2) 0.42 0.45 0.61 0.15
Mitosis, regulation of CDK activity AA608568 cyclin A2 (CCNA2) 0.36 0.42 0.44 2.90
Neurogenesis AA425008 cerebellin 1 precursor (CBLN1) 1.09 0.37 0.20 0.21
Oncogenesis W69960 Wolf–Hirschhorn syndrome candidate 1 (WHSC1) 0.12 0.10 0.05 0.10
Protein amino-acid phosphorylation AA598841 natriuretic peptide receptor A/guanylate cyclase A
(atrionatriuretic peptide receptor A) (NPR1)
0.46 0.34 0.74 0.41
Proteolysis and peptidolysis H94487 cathepsin E (CTSE) 0.79 0.39 0.34 0.12
Regulation of cell cycle H73724 cyclin-dependent kinase 6 (CDK6) 0.27 0.53 0.15 0.10
Regulation of transcription, DNA
dependent
H82435 myeloid/lymphoid or mixed-lineage leukaemia 3 (MLL3) 0.29 0.46 0.39 0.56
Regulation of transcription, DNA
dependent
AA480906 protein kinase C binding protein 1 (PRKCBP1) 0.40 0.23 1.10 0.48
Signal transduction H93332 apolipoprotein B (including Ag(x) antigen) (APOB) 0.37 0.49 0.56 0.46
Skeketal development W58032 frizzled-related protein (FRZB) 0.67 0.45 0.43 0.35
Steroid metabolism N92404 sulphotransferase, oestrogen-preferring (STE) 1.00 0.28 0.18 0.30
Unclassified AA454819 mitogen-activated protein kinase 3 (MAPK3) 0.21 0.29 0.07 0.11
Unclassified AA450024 T-cell lymphoma invasion and metastasis 2 (TIAM2) 0.16 0.17 0.04 0.07
Unclassified R89492 cytochrome P450, subfamily IIC (mephenytoin 4-
hydroxylase), polypeptide 9 (CYP2C9)
0.49 0.50 0.55 0.29
Unclassified AA487505 immunoglobulin superfamily, member 4 (IGSF4) 0.39 0.28 0.55 0.44
Unclassified AA490903 pleckstrin homology, Sec7 and coiled/coil domains, binding
protein (PSCDBP)
0.43 0.40 0.83 0.49
Unclassified AA417616 B-cell CLL/lymphoma 7A (BCL7A) 0.35 0.22 0.13 0.09
Representative functions of the genes as previously reported, accession number, gene name, and fold change of each radioresistant subline compared to their parent cell line are
shown. Only the genes that showed more than two-fold change in at least three of the four radioresistant sublines are sorted by cDNA microarray data.
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higher than those for group B (Figure 2A, P¼0.053), the
expression rates of BIRC2 for group A were significantly
higher than those for group B (Figure 2B, P¼0.025). These
results suggest that genes, which are overexpressed in radio-
resistant sublines, may reflect clinical specimens of radio-
resistant cases.
DISCUSSION
Squamous cell oesophageal cancer shows intermediate-grade
radiosensitivity, but even within the same histologic type, there
is heterogeneous radiosensitivity. Radioresistance is an obstacle
in cancer therapy and affects the curability of patients. There-
fore, it is necessary to elucidate the radioresistance mechanisms
to improve prognosis. Some investigators have tried to identify a
set of genes related to radiosensitivity by comparing expression
profiles of radiosensitive and radioresistant tumours obtained as
clinical samples before treatment using a cDNA microarray
(Hanna et al, 2001; Kitahara et al, 2002). However, it is very
difficult to distinguish whether the radioresistance was inherent
in the patient or the tissue itself or if it was acquired after
cancer therapy. Thus, we thought that it is advantageous to
compare cells of the same origin with and without radio-
resistance.
Radioresistant sublines were obtained by exposing the parent
lines to repeated fractions of 2Gy, with 5–7 days recovery allowed
between each fraction. This resulted in a statistically significant
decrease in the radiosensitivity of the four exposed sublines as
measured by clonogenic assay (Table 1). One explanation for the
increased radioresistance might be an adaptive response to
radiation, which has been observed in human lymphocytes
(Olivieri et al, 1984). However, we observed that the radioresistant
sublines maintained a radioresistant phenotype for at least 3
months after cessation of FIR. Russell et al (1995) explained that
the selective pressure of repeated irradiation favours the emer-
gence of radioresistant clones. Comparing the radioresistant
sublines with their parent cell lines, we could truly examine genes
associated with radioresistance.
A total of 19 upregulated (Table 3) and 28 downregulated
(Table 4) genes were common to radioresistant sublines. With
regard to radioresistance, malignant characteristics of cancer cells
such as resistance to apoptosis, reduced intracellular adhesion,
increased cell–matrix adhesion, and modified cell cycle are
considered to be important features. Several of the 47 genes have
been previously reported to be related to these features. The
possible involvement of other genes listed in Tables 3 and 4 to
radioresistance has not yet been reported. Other sequence tags
(ESTs) can be expected to be involved in radioresistance, but the
precise function of each gene remains unclear, so further study
would be necessary to clarify this.
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Figure 1 Quantitative RT–PCR analysis of the genes selected for cDNA
microarray data validation. (A) Relative expression rate of COX-2 was
normalised to beta-actin. (B) Relative expression rate of BIRC2 was
normalised to beta-actin. Data represent mean7standard deviation
(n¼3).
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Figure 2 Effect of radiotherapy and expression rate of COX-2 (A) and
BIRC2 (B) in clinical specimens. Expression rates were normalised to beta-
actin. The grade of radiotherapy effect was determined based on the
histopathological criteria of the Japanese Society for Esophageal Diseases.
Grade 0 (K), ineffective; Grade 1 (J), slightly effective; Grade 2 (m),
moderately effective; and Grade 3 (n), markedly effective. Group A
included patients whose histological grade after radiotherapy was either 0
or 1, and group B included patients whose grade was either 2 or 3. The
statistical analysis was performed using the Mann–Whitney U-test.
Genes in radioresistance
K Fukuda et al
1547
British Journal of Cancer (2004) 91(8), 1543–1550 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yGenes related to apoptosis and cell cycle
Prostaglandin-endoperoxide synthase (PTSG), also know as
cyclooxygenase (COX), is the key enzyme in prostaglandin
biosynthesis, and acts both as a dioxygenase and as a peroxidase.
There are two isozymes of COX: a constitutive COX-1 and an
inducible COX-2, which differ in their regulation of expression and
tissue distribution. COX-2 is expressed in a limited number of cell
types and regulated by specific stimulatory events, suggesting that
it is responsible for the prostanoid biosynthesis involved in
inflammation and mitogenesis. Recent studies have highlighted the
relevance of COX-2 in human carcinogenesis (Eberhart et al, 1994;
Ristimaki et al, 1997; Hida et al, 1998; Koga et al, 1999; Tucker et al,
1999). In oesophageal cancer, increased levels of COX-2 have also
been reported (Hwang et al, 1998; Wilson et al, 1998; Katja et al,
1999; Shamma et al, 2000). Although the role of COX-2 in
oesophageal cancer is not clear, it is possible that COX-2 is
involved in the regulation of cell survival and maintenance of
growth because COX-2 inhibitors are known to induce apoptosis
and inhibit growth in oesophageal carcinoma cells (Katja et al,
1999). Furthermore, Pyo et al (2001) showed that selective COX-2
inhibitors enhanced the radiosensitivity of rat intestinal epithelial
cells, which were stably transfected with COX-2 cDNA, and Nakata
et al (2004) reported similar findings with human A431
epidermoid carcinoma. Our data suggest that COX-2 may play
an important role in radioresistance induced by FIR, and COX-2
inhibitors may prevent tumour cells from acquiring radioresis-
tance. Furthermore, in our preliminary clinical study, the
expression rate of COX-2 tended to reflect the effect of radio-
therapy (Figure 2A, P¼0.053). Additional investigation will be
necessary to confirm this hypothesis.
BIRC2, also known as cIAP1, is a gene that encodes an
antiapoptotic molecule in the IAP family: oesophageal squamous
cell carcinoma cell lines overexpressing this gene were resistant to
apoptosis induced by chemotherapeutic reagents (Imoto et al,
2001). Furthermore, Imoto et al (2002) reported that the
expression of cIAP1 was correlated with resistance of cervical
cancers to radiotherapy. In our study, the expression rates of
BIRC2 were significantly higher in patients whose histological
grade after radiotherapy was either 0 or 1 than those patients
whose histological grade was either 2 or 3 (Figure 2B, P¼0.025).
These data also suggest that we may predict the effect of
radiotherapy using the expression rate of BIRC2.
Upregulation of ICEBERG, a caspase-1 inhibitor, and down-
regulation of caspase 6 (CASP6) are extremely intriguing.
ICEBERG proteins are intracellular regulators of caspase-1
activation and could play a role in the regulation of IL-1b
secretion and NF-kB activation during the proinflammatory
cytokine response (Humke et al, 2000; Druilhe et al, 2001), NF-
kB is a well-defined radiation-responsive transcription factor
(Thanos and Maniatis, 1995). Furthermore, NF-kB is associated
with the cell cycle, and we found that cyclin A2 (CCNA2) was
downregulated. However, genes such as p53, cyclin D1, and NF-kB
did not differ in our study, and the cell cycles of radioresistant
sublines were similar to that of parent cell lines (Table 2). Another
mechanism of cell cycle regulation may exist.
Genes related to growth and metabolism
CD73, also termed 50-nucleotidase, is a signalling pathway
metabolite in the immune response of lymphocytes. This
ectoenzyme catalyses the conversion of purine and pyrimidine
ribo- and deoxyribonucleoside monophosphates (AMP, GMP,
IMP) and leads to an elevation of the corresponding nucleosides
(adenosine) in the extracellular space, perhaps modulating
neuronal signalling and vascular perfusion, CD73 has also been
called a cellular motility factor. There is an increasing amount of
evidence for a modulatory role of PKC-mediated CD73 activity in
ischaemia, regeneration and repair, glioma cell proliferation, and
tissue invasion. Ludwig et al (1999) reported that CD73 expression
was correlated with expression of protein kinase C (PKC) and
epidermal growth factor receptor (EGFR). Protein kinase C is a
known tumour metabolite in several proliferation-promoting
pathways of EGF receptor signalling. Furthermore, Galmarini
et al (2002) reported that CD73-positive acute myeloid leukaemia
(AML) patients had worse disease-free survival and overall
survival than negative patients, and suggested that CD73 expres-
sion might be a mechanism of resistance to cytarabine. To our
knowledge, there have been no reports of an association between
radioresistance and CD73.
Genes related to cell adhesion and motility
In our study, E-cadherin (CDH1), P-cadherin (CDH3), and
protocadherin 9 (PCDH9) were downregulated in radioresistant
sublines. However, Akimoto et al (1998) reported that E-cadherin
expression was increased significantly in human squamous cell
carcinoma after irradiation. This difference might be due to
fractionated irradiation and acquisition of radioresistance. Some
studies have shown that reduced E-cadherin expression was
correlated with a high incidence of cancer metastasis and invasion
(Doki et al, 1993; Kadowaki et al, 1994), and radiation enhanced
the ability to form metastases (Sheldon and Fowler, 1976). Our
results also suggest that the tumour cells that acquired radio-
resistance may have higher invasive ability and metastatic potential.
Recently, an association between E-cadherin and COX-2 has been
reported (Tsujii and Dubois, 1995), and Noda et al (2002) found that
COX-2 inhibitors affect the transcription of E-cadherin.
Gene expression changes related to apoptosis, cell cycle, growth
metabolism, and cell adhesion are likely to contribute to the
complexity of radioresistance. It is unlikely that this phenomenon
can be explained by altered expression of a single gene: whether
this combination of gene expression changes leads to radio-
resistance of oesophageal cancers, however, is a matter to be
investigated further. Identification of such genes could lead to new
therapeutic targets.
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